Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized non-inferiority study of point-of-care ARI-0001 versus Yescarta in relapsed/refractory B-cell non-Hodgkin lymphoma
2021-000937-15Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) comparing ARI-0001 point-of-care CAR T-cell with Yescarta standard-of-care CAR T-cell (2 arms). Primary endpoint: Progression-free survival from date of investigational medicinal product infusion. Started Sep 2021; status: active.
02
Drugs
ARI-0001axicabtagene ciloleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-000937-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000937-15.